All
EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS
The European Commission has approved Rytelo treatment in transfusion-dependent anemia due to very low–, low– or intermediate-risk myelodysplastic syndrome.
Top 3 Takeaways From ASCO GU 2025
Dr. Emre Yekedüz discusses his top 3 key takeaways from attending the 2025 ASCO Genitourinary (GU) Cancers Symposium.
New Cancer Vaccine, EVM14, Cleared for Investigational Drug Application
EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach this stage.
Navigating a Diagnosis of Diabetes and Chronic Lymphocytic Leukemia
Managing diabetes and chronic lymphocytic leukemia is challenging, but with proactive care, mindfulness and diet changes, I'm working to balance both.
Olvi-Vec Shows Responses and Tolerable Safety in Small Cell Lung Cancer
Positive preliminary data from the phase 1b/2 trial evaluating Olvi-Vec in small cell lung cancer have been announced.
First Patient Dosed with Efti in Phase 3 Trial for Non-Small Cell Lung Cancer
The first patient has been dosed in the phase 3 TACTI-004 trial evaluating efti with Keytruda and chemotherapy for advanced non-small cell lung cancer.
Raising Awareness for Colorectal Cancer, On the Rise in Younger Adults
During Colorectal Cancer Awareness Month, Dr. Shyam Thakkar discussed rates of this disease in young adults, the role of AI and disparities in care.
Global Submission Seeks Approval for Sugemalimab Treatment in NSCLC
An application was submitted to the European Medicines Agency seeking approval for treatment with sugemalimab in stage 3 NSCLC following chemoradiotherapy.
Dr. Sheri Prentiss on Steps for Lymphedema Screening in Breast Cancer
Dr. Sheri Prentiss discusses what steps patients can take to ensure they're being screened for lymphedema prior to starting their breast cancer treatment.
First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
How Hope Erased My Fear of Testicular Cancer
Hope helped me navigate my testicular cancer diagnosis at 20, shaping my resilience and guiding my journey as a survivor.
Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer
Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.
Colorectal Cancer Awareness: Key Signs, Screening and Prevention
Dr. Zachariah H. Foda discusses key colorectal cancer warning signs, the rise in younger diagnoses and more.
Unraveling Disparities and Genomic Advances Across Breast Cancer Care
Dr. Regina Hampton shares case studies from her own practice, illustrating how genomic insights have improved patient outcomes in those with breast cancer.
Reducing Bowel Complications Following Radiation in Prostate Cancer
SpaceOAR Hydrogel reduced the risk of bowel disorders, the need for colonoscopy and rectal resection following radiation therapy in prostate cancer.
First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer
In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines.
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.
Advancing ctDNA for Minimal Residual Disease Detection in Breast Cancer
Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD.
Emphasizing the Importance of Breast Cancer Education and Screenings
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
The Unseen Long-Term Effects After Follicular Lymphoma Treatment
Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system impacts and lasting social effects.
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
FDA Approves Gozellix for Advanced PSMA-PET Imaging in Prostate Cancer
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.
Understanding NCCN Guidelines: Gavreto in First-Line RET Fusion NSCLC
Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.
Evolving Treatments and Advances in HER2-Positive Breast Cancer
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.
The Power of Knowledge and Staying Informed in Breast Cancer Care
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
What Patients With Breast Cancer Need to Know About Itovebi
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.
A Heaven-Sent Sign About My Brother’s Lymphoma
Cancer runs in the family, and after I’d dealt with two breast cancers, my brother came down with lymphoma.
Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.
